ロード中...
Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy
OBJECTIVES: Hydroxychloroquine (HCQ) 400 mg is approved by the Drug Controller General of India (DCGI) and recommended by the Research Society for the Study of Diabetes in India (RSSDI) clinical practice recommendations 2017 as add-on therapy after metformin and sulfonylurea in Type 2 Diabetes (T2DM...
保存先:
| 出版年: | J ASEAN Fed Endocr Soc |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Journal of the ASEAN Federation of Endocrine Societies
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784185/ https://ncbi.nlm.nih.gov/pubmed/33442141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15605/jafes.034.01.13 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|